Bio-Rad's BIO business performance has been affected by Biopharma’s softness, macroeconomic conditions in China and competitive pressure. The stock carries a Zacks Rank #4 (Sell). Since the beginning ...

Bio-Rad develops products and solutions for the life science research and clinical diagnostic markets and has niche market leadership in diagnostic quality controls, antigens, and digital polymerase ...

Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...

Bio-Rad Laboratories, Inc. BIO has been gaining from solid recovery in most of its key global markets as well as an uptick in demand for COVID-related products. The company’s focus on the ...

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. Bio-Rad's Q3 saw the company book ...

Bio-Rad Laboratories, Inc. (BIO) has experienced a rise in revenue growth in recent years thanks to strong sales of its Western Blotting, Digital PCR, and Process Media life science products. Several ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based ...